Colgate-Palmolive (India) Limited
Quality (84/100) does the heavy lifting; valuation (9/100) is the drag.
ExpensiveOvervaluedStocksWizard rates Colgate-Palmolive (India) Limited a Hold, scoring 45/100 on our blended model. On 40.3x trailing earnings it sits pricier than the Consumer Defensive median of about 26.1x. The price is about 14% below its 52-week high of ₹2,409.82 and 17% above the low of ₹1,767.86. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹2,254.62 implies about 9% upside across 26 analysts. It clears 6 of 13 investability checks, with durability 84, valuation 17 and momentum 47 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹936.12.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-13.85% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 81.6%
- Pass: Low debt (D/E < 0.5): 0.03x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 9%
- Fail: Earnings growing: -1%
- Pass: Net margin ≥ 10%: 22.0%
- Fail: Current ratio > 1.5: 1.28
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 20.04
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter51.4%
- Institutions22.7%
- Public & other25.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (81.6%).
- Lightly leveraged balance sheet.
- Healthy profit margin (22.0%).
- Financially solid — Altman Z 20.04.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~44% above our estimated fair value.
About Colgate-Palmolive (India) Limited
Colgate-Palmolive (India) Limited manufactures and distributes personal and oral care products in India. Its product portfolio includes toothpastes, toothpowder, toothbrushes, mouthwash, rinses, hand washes, and shower gels marketed under the Colgate brand, alongside soaps, cosmetics, and toilet preparations.
Colgate-Palmolive (India) Limited — frequently asked questions
Is Colgate-Palmolive (India) Limited a buy, hold or sell?
StocksWizard currently rates Colgate-Palmolive (India) Limited (COLPAL) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Colgate-Palmolive (India) Limited's fair value?
Our blended DCF and relative-valuation model estimates Colgate-Palmolive (India) Limited's fair value at about ₹1,170.15, versus a current price of ₹2,076.1 — roughly 44% downside. On that basis the stock looks overvalued by 44%.
Is Colgate-Palmolive (India) Limited financially healthy?
Colgate-Palmolive (India) Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Colgate-Palmolive (India) Limited's share price performed?
Colgate-Palmolive (India) Limited is down 4% over three months, and last traded at ₹2,076.1. Past performance doesn't predict future returns.
More in Consumer Defensive
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.